Summary by Moomoo AI
Novo Nordisk announced the termination of its CLARION-CKD phase 3 trial for ocedurenone after failing to meet its primary endpoint in treating uncontrolled hypertension in advanced chronic kidney disease patients. The company will recognize an impairment loss of approximately DKK 5.7 billion in Q2 2024, impacting operating profit growth by around 6 percentage points at CER compared to previous outlook.The decision came after an independent data monitoring committee's interim analysis revealed the trial met futility criteria, showing insufficient improvement in systolic blood pressure from baseline to week 12. The trial involved over 600 patients across 150 sites, following the same inclusion criteria as the successful phase 2b BLOCK-CKD study.Novo Nordisk is currently evaluating the potential development of ocedurenone for other indications. The company acquired the third-generation, non-steroidal mineralocorticoid receptor antagonist from KBP Biosciences in 2023. Updated financial results and outlook for 2024 will be published on August 7, 2024.
